We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

GSK-3

Glycogen synthase kinase 3 (GSK-3) inhibitors act on GSK-3α and GSK-3β, two constitutively active kinases. The serine/threonine kinase was separated in 1980 from rabbit skeletal muscle as a kinase that phosphorylates glycogen synthase. In 1995 insulin was shown to inhibit GSK-3 through protein kinase B (PKB), also known as Akt. GSK-3 also phosphorylates β-catenin and marks it for degradation, so its inhibition activates canonical Wnt signaling. In 2008 laduviglusib, also called CHIR-99021, was combined with a second kinase inhibitor to keep mouse embryonic stem cells in a ground state of self-renewal. SB 216763, TWS119, tideglusib and AR-A 014418 are further GSK-3 inhibitors for Wnt, neuronal and metabolic studies.

1 Item

  • C-Peptide 1 (rat)
    Cat. No.
    A44083
    CAS No.
    41475-27-8

    C-Peptide 1 (rat)

    C-Peptide 1 (rat) is a peptide that functions as an activator of β-catenin and GSK-3β. Its primary mechanism involves the regulation of the Wnt/β-catenin signaling pathway, which plays a crucial role in cellular processes such as proliferation and differentiation. C-Peptide 1 (rat) is utilized in cancer research, contributing to studies aimed at understanding tumorigenesis and potential therapeutic interventions.

    In stock View Details
    1 mg
    $75.00
    5 mg
    $195.00
    All 7 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...